Study shows efficacy of Aerobika device in chronic obstructive pulmonary disease- Trudell Medical

Trudell Medical International announced results from a real-world study, evaluating the efficacy of the Aerobika device in reducing chronic obstructive pulmonary disease (COPD) exacerbations. In the 6-month study, the Aerobika device demonstrated a clinically-significant reduction in exacerbations in as little as 30 days of treatment, when used as an add-on to usual COPD medications. A 6-month retrospective cohort study of the hospital Charge Detail Master (CDM) claims database, conducted between September 2013 and August 2015. This real-word study involved 810 patients, 405 receiving treatment with the Aerobika device and 405 propensity score matched controls.

The primary outcome was the proportion of patients with moderate-to-severe and severe exacerbations at 30 days. The Aerobika device has been previously validated in clinical studies, demonstrating improvements in airway ventilation, lung function and quality of life. Secondary measures included resource utilization and costs associated with exacerbations. These results were presented at the European Respiratory Society International Congress.